Heterologous prime-boost strategy to immunize very young infants against measles: Pre-clinical studies in rhesus macaques

M. F. Pasetti, A. Resendiz-Albor, K. Ramirez, R. Stout, M. Papania, R. J. Adams, F. P. Polack, B. J. Ward, D. Burt, S. Chabot, J. Ulmer, E. M. Barry, M. M. Levine

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Infants in developing countries are at high risk of developing severe clinical measles if they become infected during the "window of vulnerability" (age 4-9 months), when declining maternal antibodies do not protect against wild virus, yet impede successful immunization by attenuated measles vaccine. We developed two Sindbis replicon-based DNA vaccines expressing measles virus hemagglutinin and fusion protein with the goal of priming young infants to respond safely and effectively to subsequent boosting with attenuated measles vaccine. Intradermal prime with DNA vaccines by needle-free injection followed by aerosol or parenteral boost with licensed measles vaccine was well tolerated by juvenile and young infant rhesus macaques, and protected against clinical measles and viremia on wild-type virus challenge. A proteosome-measles vaccine administered alone (three doses) or as a boost following DNA vaccine priming was also safe and protective. These promising results pave the way for clinical trials to assess this prime-boost strategy. © 2007 American Society for Clinical Pharmacology and Therapeutics.
Original languageAmerican English
Pages (from-to)672-685
Number of pages603
JournalClinical Pharmacology and Therapeutics
DOIs
StatePublished - 1 Dec 2007
Externally publishedYes

Fingerprint

Measles Vaccine
Measles
Macaca mulatta
DNA Vaccines
Attenuated Vaccines
Viral Fusion Proteins
Viruses
Replicon
Measles virus
Viremia
Hemagglutinins
Aerosols
Developing Countries
Needles
Immunization
Mothers
Clinical Trials
Injections
Clinical Studies
Antibodies

Cite this

Pasetti, M. F. ; Resendiz-Albor, A. ; Ramirez, K. ; Stout, R. ; Papania, M. ; Adams, R. J. ; Polack, F. P. ; Ward, B. J. ; Burt, D. ; Chabot, S. ; Ulmer, J. ; Barry, E. M. ; Levine, M. M. / Heterologous prime-boost strategy to immunize very young infants against measles: Pre-clinical studies in rhesus macaques. In: Clinical Pharmacology and Therapeutics. 2007 ; pp. 672-685.
@article{266b5a1c42f54112a80e6a294a21808f,
title = "Heterologous prime-boost strategy to immunize very young infants against measles: Pre-clinical studies in rhesus macaques",
abstract = "Infants in developing countries are at high risk of developing severe clinical measles if they become infected during the {"}window of vulnerability{"} (age 4-9 months), when declining maternal antibodies do not protect against wild virus, yet impede successful immunization by attenuated measles vaccine. We developed two Sindbis replicon-based DNA vaccines expressing measles virus hemagglutinin and fusion protein with the goal of priming young infants to respond safely and effectively to subsequent boosting with attenuated measles vaccine. Intradermal prime with DNA vaccines by needle-free injection followed by aerosol or parenteral boost with licensed measles vaccine was well tolerated by juvenile and young infant rhesus macaques, and protected against clinical measles and viremia on wild-type virus challenge. A proteosome-measles vaccine administered alone (three doses) or as a boost following DNA vaccine priming was also safe and protective. These promising results pave the way for clinical trials to assess this prime-boost strategy. {\circledC} 2007 American Society for Clinical Pharmacology and Therapeutics.",
author = "Pasetti, {M. F.} and A. Resendiz-Albor and K. Ramirez and R. Stout and M. Papania and Adams, {R. J.} and Polack, {F. P.} and Ward, {B. J.} and D. Burt and S. Chabot and J. Ulmer and Barry, {E. M.} and Levine, {M. M.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1038/sj.clpt.6100420",
language = "American English",
pages = "672--685",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Wiley-Blackwell",

}

Pasetti, MF, Resendiz-Albor, A, Ramirez, K, Stout, R, Papania, M, Adams, RJ, Polack, FP, Ward, BJ, Burt, D, Chabot, S, Ulmer, J, Barry, EM & Levine, MM 2007, 'Heterologous prime-boost strategy to immunize very young infants against measles: Pre-clinical studies in rhesus macaques', Clinical Pharmacology and Therapeutics, pp. 672-685. https://doi.org/10.1038/sj.clpt.6100420

Heterologous prime-boost strategy to immunize very young infants against measles: Pre-clinical studies in rhesus macaques. / Pasetti, M. F.; Resendiz-Albor, A.; Ramirez, K.; Stout, R.; Papania, M.; Adams, R. J.; Polack, F. P.; Ward, B. J.; Burt, D.; Chabot, S.; Ulmer, J.; Barry, E. M.; Levine, M. M.

In: Clinical Pharmacology and Therapeutics, 01.12.2007, p. 672-685.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Heterologous prime-boost strategy to immunize very young infants against measles: Pre-clinical studies in rhesus macaques

AU - Pasetti, M. F.

AU - Resendiz-Albor, A.

AU - Ramirez, K.

AU - Stout, R.

AU - Papania, M.

AU - Adams, R. J.

AU - Polack, F. P.

AU - Ward, B. J.

AU - Burt, D.

AU - Chabot, S.

AU - Ulmer, J.

AU - Barry, E. M.

AU - Levine, M. M.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Infants in developing countries are at high risk of developing severe clinical measles if they become infected during the "window of vulnerability" (age 4-9 months), when declining maternal antibodies do not protect against wild virus, yet impede successful immunization by attenuated measles vaccine. We developed two Sindbis replicon-based DNA vaccines expressing measles virus hemagglutinin and fusion protein with the goal of priming young infants to respond safely and effectively to subsequent boosting with attenuated measles vaccine. Intradermal prime with DNA vaccines by needle-free injection followed by aerosol or parenteral boost with licensed measles vaccine was well tolerated by juvenile and young infant rhesus macaques, and protected against clinical measles and viremia on wild-type virus challenge. A proteosome-measles vaccine administered alone (three doses) or as a boost following DNA vaccine priming was also safe and protective. These promising results pave the way for clinical trials to assess this prime-boost strategy. © 2007 American Society for Clinical Pharmacology and Therapeutics.

AB - Infants in developing countries are at high risk of developing severe clinical measles if they become infected during the "window of vulnerability" (age 4-9 months), when declining maternal antibodies do not protect against wild virus, yet impede successful immunization by attenuated measles vaccine. We developed two Sindbis replicon-based DNA vaccines expressing measles virus hemagglutinin and fusion protein with the goal of priming young infants to respond safely and effectively to subsequent boosting with attenuated measles vaccine. Intradermal prime with DNA vaccines by needle-free injection followed by aerosol or parenteral boost with licensed measles vaccine was well tolerated by juvenile and young infant rhesus macaques, and protected against clinical measles and viremia on wild-type virus challenge. A proteosome-measles vaccine administered alone (three doses) or as a boost following DNA vaccine priming was also safe and protective. These promising results pave the way for clinical trials to assess this prime-boost strategy. © 2007 American Society for Clinical Pharmacology and Therapeutics.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=36148931379&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=36148931379&origin=inward

U2 - 10.1038/sj.clpt.6100420

DO - 10.1038/sj.clpt.6100420

M3 - Article

C2 - 17971812

SP - 672

EP - 685

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -